Methylphenidate
Methylphenidate (Ritalin, Concerta) is a prescription stimulant for ADHD and narcolepsy; misuse strains the heart, can cause dependence and psychosis, and is risky combined with other drugs.
Overview
Methylphenidate is a prescription stimulant sold under brand names including Ritalin and Concerta, used to treat attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. Taken as prescribed under medical supervision it can improve attention and reduce impulsivity and hyperactivity, and it is one of the most commonly prescribed ADHD medications. Like amphetamine-based stimulants, it is a controlled substance with a recognized potential for misuse, dependence, and addiction, and regulators have strengthened warnings about the serious risks of prescription stimulants. Misuse — taking more than prescribed, using it without a prescription (for example to study or stay awake), or taking it by non-oral routes — substantially raises the risks.
Source: NIDA; FDA; PubChem CID 4158
Chemistry & mechanism of action
Methylphenidate increases the activity of the neurotransmitters dopamine and norepinephrine in the brain, chiefly by blocking their reuptake so they remain active longer. This boosts alertness and attention and, at higher doses, can produce euphoria that reinforces repeated use. In people with ADHD, carefully dosed stimulant medication can improve focus and impulse control; the same mechanisms, at higher or misused doses, drive the drug's dangers — cardiovascular stimulation that raises heart rate and blood pressure, agitation, and, with heavy use, disruption of normal dopamine signaling. Repeated misuse can produce tolerance and dependence.
Source: NIDA; PubChem CID 4158
Effects
At therapeutic doses, methylphenidate improves attention and wakefulness and can reduce appetite. Common effects, especially at higher or misused doses, include increased energy and alertness, euphoria, reduced appetite, insomnia, dry mouth, headache, and a faster heartbeat. As the dose rises, effects can include anxiety, restlessness, irritability, raised blood pressure, and — at high doses or with heavy use — paranoia, hallucinations, and stimulant psychosis. Coming down can bring fatigue, low mood, and difficulty concentrating. Long-term misuse is associated with cardiovascular strain, weight loss, sleep disruption, and mental-health effects.
Source: NIDA; FDA
Risks & harms
The main acute danger is cardiovascular: methylphenidate raises heart rate and blood pressure and can, particularly at high doses or in people with underlying heart conditions, contribute to dangerously high blood pressure, irregular heart rhythms, heart attack, stroke, seizures, or dangerously high body temperature. Unlike opioids, there is no reversal medication for a stimulant overdose — emergency care is the response, so chest pain, severe agitation, very high temperature, or seizures mean calling 911. Combining methylphenidate with other stimulants (including amphetamines, cocaine, or large amounts of caffeine) compounds cardiovascular strain, and combining it with opioids or other depressants is dangerous because the stimulant can mask sedation and lead to taking more of the depressant. Heavy or high-dose use can trigger stimulant psychosis, and misuse can lead to dependence. Any pill obtained outside a licensed pharmacy can be counterfeit and may contain other substances, including fentanyl, so naloxone is worth having on hand. For poisoning guidance call Poison Control at 1-800-222-1222; for substance-use support the SAMHSA National Helpline is 1-800-662-4357.
Source: NIDA; FDA; SAMHSA
Legal status (US)
In the United States, methylphenidate is a Schedule II controlled substance under the Controlled Substances Act: it has accepted medical uses but a high potential for abuse and dependence, so it is tightly regulated, prescriptions cannot be refilled, and possessing or sharing it without a valid prescription is illegal. Internationally, methylphenidate is controlled under the United Nations Convention on Psychotropic Substances (1971), with penalties varying by country. For country-by-country legal detail, see our legality pages.
Source: DEA; UN Convention on Psychotropic Substances (1971)
Drug laws and enforcement change and vary by country. This is not legal advice. Always confirm with the destination’s embassy or official drug authority before traveling, because penalties can be severe, including imprisonment.
Before you travel
Verify current rules with the destination country’s official drug authority and your own country’s embassy before traveling. Find the destination’s U.S. embassy & official country guidance →
Non-U.S. travelers: check your own government’s travel advisory and embassy.
If you’re detained or arrested abroad
Contact your own country’s embassy or consulate in the destination immediately, not the destination’s authorities. U.S. citizens: contact the nearest U.S. embassy/consulate and the U.S. State Department at +1-202-501-4444 (from abroad). If a U.S. citizen is arrested or detained abroad →
Images
Visual references coming soon.
If it’s too intense
If an experience becomes overwhelming, the goal is to stay safe and let it pass, most difficult experiences ease as the drug wears off.
- Get to a calm, safe space with someone you trust who is sober and can stay with you.
- Cool down if you’re overheating, move somewhere cool, remove extra layers, rest. Overheating is especially a risk with stimulants and MDMA.
- Sip water to thirst, but don’t over-hydrate. Drinking large amounts of plain water (especially after MDMA) can dangerously dilute your blood sodium (hyponatremia). Electrolytes help more than volume.
- Slow your breathing, long, slow exhales help settle a racing heart and anxiety.
- A sugary drink, fruit juice, or a snack can ease shakiness and the anxiety that comes with low blood sugar.
- Do not take more, and do not add another substance to manage it. Redosing or adding something else (including a sedative like a benzodiazepine) can make things worse, not better.
With stimulants, overheating and a racing heart are the main concerns, get somewhere cool, stop any physical activity, and don't take more.
Source: general harm-reduction guidance from SAMHSA, NIH/NIDA, and MedlinePlus, in our own words. Draft, not yet medically reviewed.
Forensic dossier
Draft · every field is source-cited or marked “Unknown, pending review”Identity
- PubChem CID
- 4158PubChem PUG-REST ↗ · retrieved 2026-06-18
- IUPAC name
- methyl 2-phenyl-2-piperidin-2-ylacetatePubChem PUG-REST ↗ · retrieved 2026-06-18
- Molecular formula
- C14H19NO2PubChem PUG-REST ↗ · retrieved 2026-06-18
- SMILES
- COC(=O)C(C1CCCCN1)C2=CC=CC=C2PubChem PUG-REST ↗ · retrieved 2026-06-18
- InChIKey
- DUGOZIWVEXMGBE-UHFFFAOYSA-NPubChem PUG-REST ↗ · retrieved 2026-06-18
- Synonyms / aliases
- ritalin, concerta, Methylphenidan, Phenidylate, Calocain, Plimasine, Methyl phenidylacetate, Metilfenidato, Methylphenidatum, Methyl phenidate, Daytrana, Cotempla XR-ODTPubChem PUG-REST + seed aliases ↗ · retrieved 2026-06-18
Composition
- Composition
- N/A — single compound (see Identity)
Physical / pill characteristics
- Dosage form
- 3 DOSAGE FORMS AND STRENGTHS 10 mg extended-release capsules light brown opaque cap and white opaque body, imprinted TEVA on the cap and 5345 on the body 20 mg openFDA drug label ↗ · retrieved 2026-06-18
- Shape
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
- Color
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
- Imprint
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
- Score
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
Scheduling & legal status
- US schedule
- Unknown — pending review
- International
- Unknown, pending review
Effects, risks & interactions
- Effects
- Methylphenidate is a prescription stimulant for ADHD and narcolepsy that works by a different mechanism from the amphetamines: instead of forcing neurotransmitter release, it blocks the reuptake of dopamine and noradrenaline, raising their levels in the brain. Its felt effects are stimulant — sharper focus and attention, wakefulness, reduced hunger, and a faster, higher-pressure pulse — but the reuptake-inhibition mechanism sets it apart pharmacologically from amphetamine and the amphetamine-salt products.PubChem CID 4158 + DailyMed label ↗ · retrieved 2026-06-18
- Risks
- Like other stimulants, methylphenidate's chief dangers are cardiovascular: it drives pulse and blood pressure upward and, particularly with pre-existing heart disease, can bring arrhythmia, heart attack and stroke, with sudden cardiac events reported in people who have structural heart abnormalities. It can cause agitation and, at high or chronic doses, a stimulant psychosis involving new or worsened paranoia or hallucinations. It carries a potential for misuse and dependence, and commonly suppresses appetite and disturbs sleep.PubChem CID 4158 + DailyMed label ↗ · retrieved 2026-06-18
- Interactions
- Methylphenidate's labelling directs that it not be used with monoamine-oxidase inhibitors, or within two weeks of them, because of the hypertensive-crisis risk that stimulants pose in that combination. It also cautions that methylphenidate can reduce the effect of medicines taken to lower blood pressure, so blood pressure should be monitored and the antihypertensive dose adjusted as needed when they are used together.DailyMed §7 Drug Interactions ↗ · retrieved 2026-06-18
Pill catalog
Rx/OTC variants · openFDA + DailyMed (public domain) · draft, pending reviewThis drug comes in 221different versions. Make sure you’re looking at the right one, use the search above to find your exact pill by imprint, color, or shape.
Showing 24 of 221 variants
- Strength
- METHYLPHENIDATE HYDROCHLORIDE 20 mg/1
- Imprint
- 20 MG M 1820
- Color
- blue
- Shape
- CAPSULE
- Form
- CAPSULE, EXTENDED RELEASE
- Labeler
- SpecGx LLC
- Schedule
- CII
- NDC
- 0406-1820 ↗ · 2026-06-18
- Strength
- METHYLPHENIDATE HYDROCHLORIDE 60 mg/1
- Imprint
- A902 60 mg
- Color
- white
- Shape
- CAPSULE
- Form
- CAPSULE, EXTENDED RELEASE
- Labeler
- Actavis Pharma, Inc.
- Schedule
- CII
- NDC
- 0591-3902 ↗ · 2026-06-18
- Strength
- METHYLPHENIDATE HYDROCHLORIDE 10 mg/1
- Imprint
- FM4
- Color
- white
- Shape
- ROUND
- Form
- TABLET, EXTENDED RELEASE
- Labeler
- Golden State Medical Supply, Inc.
- Schedule
- CII
- NDC
- 51407-527 ↗ · 2026-06-18
- Strength
- METHYLPHENIDATE HYDROCHLORIDE 20 mg/1
- Imprint
- FM5
- Color
- white
- Shape
- ROUND
- Form
- TABLET, EXTENDED RELEASE
- Labeler
- Golden State Medical Supply, Inc.
- Schedule
- CII
- NDC
- 51407-528 ↗ · 2026-06-18
- Strength
- METHYLPHENIDATE HYDROCHLORIDE 27 mg/1
- Imprint
- TL707
- Color
- gray
- Shape
- ROUND
- Form
- TABLET, EXTENDED RELEASE
- Labeler
- Golden State Medical Supply, Inc.
- Schedule
- CII
- NDC
- 51407-925 ↗ · 2026-06-18
- Strength
- METHYLPHENIDATE HYDROCHLORIDE 20 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Bryant Ranch Prepack
- Schedule
- CII
- NDC
- 72162-2087 ↗ · 2026-06-18
- Strength
- METHYLPHENIDATE HYDROCHLORIDE 18 mg/1
- Imprint
- TL706
- Color
- yellow
- Shape
- ROUND
- Form
- TABLET, EXTENDED RELEASE
- Labeler
- Golden State Medical Supply, Inc.
- Schedule
- CII
- NDC
- 51407-924 ↗ · 2026-06-18
- Strength
- METHYLPHENIDATE HYDROCHLORIDE 10 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Bryant Ranch Prepack
- Schedule
- CII
- NDC
- 72162-2086 ↗ · 2026-06-18
- Strength
- METHYLPHENIDATE HYDROCHLORIDE 36 mg/1
- Imprint
- TL708
- Color
- white
- Shape
- ROUND
- Form
- TABLET, EXTENDED RELEASE
- Labeler
- Golden State Medical Supply, Inc.
- Schedule
- CII
- NDC
- 51407-926 ↗ · 2026-06-18
- Strength
- METHYLPHENIDATE HYDROCHLORIDE 10 mg/1
- Imprint
- 1423 M
- Color
- white
- Shape
- ROUND
- Form
- TABLET, EXTENDED RELEASE
- Labeler
- SpecGx LLC
- Schedule
- CII
- NDC
- 0406-1445 ↗ · 2026-06-18
- Strength
- METHYLPHENIDATE HYDROCHLORIDE 54 mg/1
- Imprint
- TL709
- Color
- pink
- Shape
- ROUND
- Form
- TABLET, EXTENDED RELEASE
- Labeler
- Golden State Medical Supply, Inc.
- Schedule
- CII
- NDC
- 51407-927 ↗ · 2026-06-18
- Strength
- METHYLPHENIDATE HYDROCHLORIDE 20 mg/1
- Imprint
- 1451 M
- Color
- white
- Shape
- ROUND
- Form
- TABLET, EXTENDED RELEASE
- Labeler
- SpecGx LLC
- Schedule
- CII
- NDC
- 0406-1473 ↗ · 2026-06-18
- Strength
- METHYLPHENIDATE HYDROCHLORIDE 72 mg/1
- Imprint
- 72
- Color
- blue
- Shape
- ROUND
- Form
- TABLET, EXTENDED RELEASE
- Labeler
- Northstar Rx LLC
- Schedule
- CII
- NDC
- 72603-399 ↗ · 2026-06-18
- Strength
- METHYLPHENIDATE HYDROCHLORIDE 10 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET, CHEWABLE
- Labeler
- Bryant Ranch Prepack
- Schedule
- CII
- NDC
- 72162-1306 ↗ · 2026-06-18
- Strength
- METHYLPHENIDATE HYDROCHLORIDE 10 mg/1
- Imprint
- 10 MG M 1810
- Color
- green
- Shape
- CAPSULE
- Form
- CAPSULE, EXTENDED RELEASE
- Labeler
- SpecGx LLC
- Schedule
- CII
- NDC
- 0406-1810 ↗ · 2026-06-18
- Strength
- METHYLPHENIDATE HYDROCHLORIDE 5 mg/1
- Imprint
- NP018 5
- Color
- yellow
- Shape
- ROUND
- Form
- TABLET
- Labeler
- Neolpharma, Inc.
- Schedule
- CII
- NDC
- 55466-101 ↗ · 2026-06-18
- Strength
- METHYLPHENIDATE HYDROCHLORIDE 36 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET, EXTENDED RELEASE
- Labeler
- Bryant Ranch Prepack
- Schedule
- CII
- NDC
- 72162-2394 ↗ · 2026-06-18
- Strength
- METHYLPHENIDATE HYDROCHLORIDE 27 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET, EXTENDED RELEASE
- Labeler
- Bryant Ranch Prepack
- Schedule
- CII
- NDC
- 72162-2395 ↗ · 2026-06-18
- Strength
- METHYLPHENIDATE HYDROCHLORIDE 10 mg/1
- Imprint
- NP019 10
- Color
- white
- Shape
- ROUND
- Form
- TABLET
- Labeler
- Neolpharma, Inc.
- Schedule
- CII
- NDC
- 55466-102 ↗ · 2026-06-18
- Strength
- METHYLPHENIDATE HYDROCHLORIDE 20 mg/1
- Imprint
- NP020 20
- Color
- yellow
- Shape
- ROUND
- Form
- TABLET
- Labeler
- Neolpharma, Inc.
- Schedule
- CII
- NDC
- 55466-103 ↗ · 2026-06-18
- Strength
- METHYLPHENIDATE HYDROCHLORIDE 20 mg/1
- Imprint
- CIBA 34
- Color
- YELLOW
- Shape
- ROUND
- Form
- TABLET
- Labeler
- Sandoz Inc
- Schedule
- CII
- NDC
- 66758-275 ↗ · 2026-06-18
- Strength
- METHYLPHENIDATE HYDROCHLORIDE 5 mg/1
- Imprint
- CIBA 7
- Color
- YELLOW
- Shape
- ROUND
- Form
- TABLET
- Labeler
- Sandoz Inc
- Schedule
- CII
- NDC
- 66758-273 ↗ · 2026-06-18
- Strength
- METHYLPHENIDATE HYDROCHLORIDE 10 mg/1
- Imprint
- CIBA 3
- Color
- GREEN
- Shape
- ROUND
- Form
- TABLET
- Labeler
- Sandoz Inc
- Schedule
- CII
- NDC
- 66758-274 ↗ · 2026-06-18
- Strength
- METHYLPHENIDATE HYDROCHLORIDE 30 mg/1
- Imprint
- 30 MG M 1830
- Color
- red
- Shape
- CAPSULE
- Form
- CAPSULE, EXTENDED RELEASE
- Labeler
- SpecGx LLC
- Schedule
- CII
- NDC
- 0406-1830 ↗ · 2026-06-18
Dosage
Pending medical reviewer
